

Matthias Oelke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6143082/publications.pdf>

Version: 2024-02-01

59
papers

4,457
citations

172207

29
h-index

110170

64
g-index

69
all docs

69
docs citations

69
times ranked

3666
citing authors

#	ARTICLE	IF	CITATIONS
1	EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic Obstruction. <i>European Urology</i> , 2013, 64, 118-140.	0.9	990
2	EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. <i>European Urology</i> , 2015, 67, 1099-1109.	0.9	735
3	The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction. <i>Neurourology and Urodynamics</i> , 2019, 38, 433-477.	0.8	446
4	Monotherapy with Tadalafil or Tamsulosin Similarly Improved Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia in an International, Randomised, Parallel, Placebo-Controlled Clinical Trial. <i>European Urology</i> , 2012, 61, 917-925.	0.9	253
5	Age and Bladder Outlet Obstruction Are Independently Associated with Detrusor Overactivity in Patients with Benign Prostatic Hyperplasia. <i>European Urology</i> , 2008, 54, 419-426.	0.9	162
6	Increase in detrusor wall thickness indicates bladder outlet obstruction (BOO) in men. <i>World Journal of Urology</i> , 2002, 19, 443-452.	1.2	144
7	The Underactive Bladder: A New Clinical Concept?. <i>European Urology</i> , 2015, 68, 351-353.	0.9	123
8	Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. <i>European Urology</i> , 2016, 70, 124-133.	0.9	106
9	Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014). <i>Age and Ageing</i> , 2015, 44, 745-755.	0.7	105
10	Age-stratified normal values for prostate volume, PSA, maximum urinary flow rate, IPSS, and other LUTS/BPH indicators in the German male community-dwelling population aged 50 years or older. <i>World Journal of Urology</i> , 2011, 29, 171-178.	1.2	83
11	A practical approach to the management of nocturia. <i>International Journal of Clinical Practice</i> , 2017, 71, e13027.	0.8	76
12	Long-term Safety and Efficacy of Single-tablet Combinations of Solifenacin and Tamsulosin Oral Controlled Absorption System in Men with Storage and Voiding Lower Urinary Tract Symptoms: Results from the NEPTUNE Study and NEPTUNE II Open-label Extension. <i>European Urology</i> , 2015, 67, 262-270.	0.9	64
13	Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 197-204.	1.1	52
14	Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies. <i>Therapeutic Advances in Urology</i> , 2017, 9, 137-154.	0.9	43
15	Nocturia: state of the art and critical analysis of current assessment and treatment strategies. <i>World Journal of Urology</i> , 2014, 32, 1109-1117.	1.2	41
16	Cardiovascular and ocular safety of α_1 -adrenoceptor antagonists in the treatment of male lower urinary tract symptoms. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 1187-1197.	1.0	41
17	Unravelling detrusor underactivity: Development of a bladder outlet resistance "Bladder contractility nomogram for adult male patients with lower urinary tract symptoms. <i>Neurourology and Urodynamics</i> , 2016, 35, 980-986.	0.8	41
18	Can we identify men who will have complications from benign prostatic obstruction (BPO)? ICIERS 2011. <i>Neurourology and Urodynamics</i> , 2012, 31, 322-326.	0.8	38

#	ARTICLE	IF	CITATIONS
19	Detrusor contraction power parameters (BCI and W max) rise with increasing bladder outlet obstruction grade in men with lower urinary tract symptoms: results from a urodynamic database analysis. <i>World Journal of Urology</i> , 2014, 32, 1177-1183.	1.2	36
20	Effects of Tadalafil Once Daily on Maximum Urinary Flow Rate in Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia. <i>Journal of Urology</i> , 2014, 191, 1045-1050.	0.2	35
21	Nocturia and its impact on health-related quality of life and health care seeking behaviour in German community-dwelling men aged 50 years or older. <i>World Journal of Urology</i> , 2014, 32, 1155-1162.	1.2	34
22	Time to Onset of Clinically Meaningful Improvement with Tadalafil 5 mg Once Daily for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Analysis of Data Pooled from 4 Pivotal, Double-Blind, Placebo Controlled Studies. <i>Journal of Urology</i> , 2015, 193, 1581-1589.	0.2	32
23	Review on ultrasound measurement of bladder or detrusor wall thickness in women: techniques, diagnostic utility, and use in clinical trials. <i>World Journal of Urology</i> , 2013, 31, 1093-1104.	1.2	31
24	Treatment satisfaction with tadalafil or tamsulosin vs placebo in men with lower urinary tract symptoms (<scp>LUTS</scp>) suggestive of benign prostatic hyperplasia (<scp>BPH</scp>): results from a randomised, placebo-controlled study. <i>BJU International</i> , 2014, 114, 568-575.	1.3	31
25	Effects of tadalafil on nighttime voiding (nocturia) in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a post hoc analysis of pooled data from four randomized, placebo-controlled clinical studies. <i>World Journal of Urology</i> , 2014, 32, 1127-1132.	1.2	30
26	Ultrasound detrusor wall thickness measurement in combination with bladder capacity can safely detect detrusor underactivity in adult men. <i>World Journal of Urology</i> , 2017, 35, 153-159.	1.2	30
27	Diagnosis and medical treatment of lower urinary tract symptoms in adult men: applying specialist guidelines in clinical practice. <i>BJU International</i> , 2012, 110, 710-718.	1.3	29
28	Nocturia is often inadequately assessed, diagnosed and treated by physicians: results of an observational, real-life practice database containing 8659 European and <scp>US</scp> American patients. <i>International Journal of Clinical Practice</i> , 2016, 70, 940-949.	0.8	29
29	Bladder Instillation Therapy With Hyaluronic Acid and Chondroitin Sulfate Improves Symptoms of Postradiation Cystitis: Prospective Pilot Study. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 444-449.	0.9	27
30	Efficacy and safety of tadalafil 5 mg once daily in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in men aged ≥75 years: integrated analyses of pooled data from multinational, randomized, placebo-controlled clinical studies. <i>BJU International</i> , 2017, 119, 793-803.	1.3	27
31	Acute Urinary Retention Rates in the General Male Population and in Adult Men With Lower Urinary Tract Symptoms Participating in Pharmacotherapy Trials: A Literature Review. <i>Urology</i> , 2015, 86, 654-665.	0.5	26
32	Efficacy of propiverine ER with or without β -blockers related to maximum urinary flow rate in adult men with OAB: results of a 12-week, multicenter, non-interventional study. <i>World Journal of Urology</i> , 2011, 29, 217-223.	1.2	21
33	Nocturia improvement in the combination of Avodart® and tamsulosin (CombAT) study. <i>World Journal of Urology</i> , 2014, 32, 1133-1140.	1.2	21
34	Impact of dutasteride on nocturia in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): a pooled analysis of three phase III studies. <i>World Journal of Urology</i> , 2014, 32, 1141-1147.	1.2	20
35	Sodium hyaluronate and chondroitin sulfate replenishment therapy can improve nocturia in men with post-radiation cystitis: results of a prospective pilot study. <i>BMC Urology</i> , 2015, 15, 65.	0.6	20
36	Efficacy of Continuous Dosing of Tadalafil Once Daily vs Tadalafil On Demand in Clinical Subgroups of Men with Erectile Dysfunction: A Descriptive Comparison Using the Integrated Tadalafil Databases. <i>Journal of Sexual Medicine</i> , 2016, 13, 860-875.	0.3	20

#	ARTICLE	IF	CITATIONS
37	Exploratory Decision-Tree Modeling of Data from the Randomized REACTT Trial of Tadalafil Versus Placebo to Predict Recovery of Erectile Function After Bilateral Nerve-Sparing Radical Prostatectomy. <i>European Urology</i> , 2016, 70, 529-537.	0.9	20
38	The use of a single daily dose of tadalafil to treat signs and symptoms of benign prostatic hyperplasia and erectile dysfunction. <i>Research and Reports in Urology</i> , 2013, 5, 99.	0.6	18
39	Incidence of urinary retention during treatment with single tablet combinations of solifenacin+tamsulosin OCASâ„¢ for up to 1 year in adult men with both storage and voiding LUTS: A subanalysis of the NEPTUNE/NEPTUNE II randomized controlled studies. <i>PLoS ONE</i> , 2017, 12, e0170726.	1.1	18
40	PETROLEUM JELLY IS AN IDEAL CONTACT MEDIUM FOR PAIN REDUCTION AND SUCCESSFUL TREATMENT WITH EXTRACORPOREAL SHOCK WAVE LITHOTRIPSY. <i>Journal of Urology</i> , 1999, 162, 18-22.	0.2	17
41	Manual versus automatic bladder wall thickness measurements: a method comparison study. <i>World Journal of Urology</i> , 2009, 27, 747-53.	1.2	17
42	Bladder wall thickness in women with symptoms of overactive bladder and detrusor overactivity: Results from the randomised, placebo-controlled shrink study. <i>Neurourology and Urodynamics</i> , 2016, 35, 819-825.	0.8	16
43	Effects of Tadalafil Once-Daily or On-Demand vs Placebo on Return to Baseline Erectile Function After Bilateral Nerve-Sparing Radical Prostatectomy – Results from a Randomized Controlled Trial (REACTT). <i>Journal of Sexual Medicine</i> , 2016, 13, 679-683.	0.3	16
44	Annual direct and indirect costs attributable to nocturia in Germany, Sweden, and the UK. <i>European Journal of Health Economics</i> , 2017, 18, 761-771.	1.4	16
45	Recommendations for future development of contractility and obstruction nomograms for women. ICI-RS 2014. <i>Neurourology and Urodynamics</i> , 2016, 35, 307-311.	0.8	14
46	Responder and health-related quality of life analyses in men with lower urinary tract symptoms treated with a fixed-dose combination of solifenacin and tamsulosin oral-controlled absorption system: results from the NEPTUNE study. <i>BJU International</i> , 2016, 117, 165-172.	1.3	14
47	Fixed-dose combination PRO 160/120 of sabal and urtica extracts improves nocturia in men with LUTS suggestive of BPH: re-evaluation of four controlled clinical studies. <i>World Journal of Urology</i> , 2014, 32, 1149-1154.	1.2	13
48	Impact of cardiovascular risk factors and related comorbid conditions and medical therapy reported at baseline on the treatment response to tadalafil 5Åmg once-daily in men with lower urinary tract symptoms associated with benign prostatic hyperplasia: an. <i>International Journal of Clinical Practice</i> , 2015, 69, 1496-1507.	0.8	13
49	Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people >65 years of age: A post hoc analysis of data from the SOFIA study. <i>Neurourology and Urodynamics</i> , 2015, 34, 438-443.	0.8	12
50	Use of Structural Equation Modeling to Demonstrate the Differential Impact of Storage and Voiding Lower Urinary Tract Symptoms on Symptom Bother and Quality of Life during Treatment for Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia. <i>Journal of Urology</i> , 2016, 196, 824-830.	0.2	10
51	Intradetrusor onabotulinumtoxinA injections are significantly more efficacious than oral oxybutynin for treatment of neurogenic detrusor overactivity: results of a randomized, controlled, 24-week trial. <i>Einstein (Sao Paulo, Brazil)</i> , 2018, 16, eAO4207.	0.3	10
52	Expression and Distribution of Phosphodiesterase Isoenzymes in the Human Male Urethra. <i>Urology</i> , 2015, 85, 964.e1-964.e6.	0.5	7
53	Phosphodiesterase isoenzymes in the human urethra: A molecular biology and functional study. <i>European Journal of Pharmacology</i> , 2014, 741, 330-335.	1.7	6
54	What is the role of combination drug therapy in the treatment of overactive bladder? ICI-RS 2014. <i>Neurourology and Urodynamics</i> , 2016, 35, 288-292.	0.8	6

#	ARTICLE	IF	CITATIONS
55	What uro-gynecologists should know about sacral neuromodulation (SNM) for the treatment of refractory overactive bladder. Archives of Gynecology and Obstetrics, 2019, 299, 1243-1252.	0.8	5
56	Latest Developments in the Assessment and Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: What is Clinically Relevant?. Clinical Drug Investigation, 2015, 35, 3-6.	1.1	2
57	Editorial comment on Wada N, Kita M, Hashizume K, et al. Urodynamic effects of dutasteride add-on therapy to alpha-adrenergic antagonist for patients with benign prostatic enlargement: Prospective pressure-flow study. Neurourol Urodyn 2013;32:1123-1127. Neurourology and Urodynamics. 2013, 32, 1128-1129.	0.8	1
58	Re: Dutasteride Improves Outcomes of Benign Prostatic Hyperplasia When Evaluated for Prostate Cancer Risk Reduction: Secondary Analysis of the Reduction by Dutasteride of Prostate Cancer Events Trial. European Urology, 2012, 61, 624-625.	0.9	0
59	Re: Editorial Comment on Monotherapy with Tadalafil or Tamsulosin Similarly Improved Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia in an International, Randomised, Parallel, Placebo-Controlled Clinical Trial (Eur Urol 2012; 61: 917-925). Journal of Urology, 2013, 190, 2311-2312.	0.2	0